Trial Profile
A phase II randomised, double-blind, stratified, multi-centre trial comparing the Nolvadex [tamoxifen] 20 mg and placebo combination to the Nolvadex 20 mg and ZD1839 [gefitinib] (IRESSA) 250 mg combination in patients with metastatic breast cancer and oestrogen receptor (ER) and/or progesterone (PR) positive tumors.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary) ; Tamoxifen
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 17 Jul 2007 Status changed from in progress to completed.
- 23 Nov 2006 Status change
- 15 Dec 2005 New trial record.